Denmark Sweden Norway Finland  Genzyme Danmark HomeKontaktGenzyme Corporate Home
OM OS
BEHANDLINGSOMRÅDER
PRODUKTER
Genzyme  
Genzyme er ét af verdens førende bioteknologiske firmaer og vores mål, er at forbedre livet for patienter med alvorlige sygdomme. Læs mere her
 
NYHEDER
PRESSEMEDDELSE
At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada (alemtuzumab) in Pivotal Studies


In approximately 70 percent of patients, disability scores improved or remained stable for an additional two years beyond the two-year pivotal multiple sclerosis studies.

Approximately 70 percent of patients treated with Lemtrada (alemtuzumab) did not receive a third course of treatment through the second year of the extension.


Cambridge, Mass. - September 11, 2014 – Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today positive interim results from the second year of the extension study of Lemtrada™ (alemtuzumab) for multiple sclerosis.
Mere >

genzyme i
norden
genzyme
biosurgery
genzyme
corporation
 

Terms and Conditions Privacy Policy © 2008 Genzyme. All Rights Reserved. Webmaster